International Conference and Expo on Parenterals & Injectables August 17-19, 2015 Chicago, USA

OMICS Group is one of the leading scientific event organizers, which conducts over 300 scientific conferences all over the globe. OMICS Publishing Group hosts 400 Open Access journals with over 5 million readers and the renown and success of the same can be attributed to the strong editorial board which contains over 35000 eminent personalities. OMICS Group International events provide exciting opportunity to showcase the services of your company to the broad International audience. OMICS group is a renowned organization that organizes highly notable pharmaceutical conferences throughout the globe.

OMICS Group Conferences invites all the participants across the globe to attend International Conference and Expo on Parenterals and Injectables during August 17-19, 2015, Chicago, USA. Parenterals-2015 is a prodigious meeting, which in-sync different fields of the pharmacy and pharmaceutical sciences alongside the companies, institutes and highly affiliated universities. Injectables conference is a podium for the desired individuals and firms around the world to share experiences, collaboration among firms and to get pharmaceutical updates with the aid of prompt keynote presentations, Oral talks and Poster presentations.
Conference series is supported with related journals and their editorial board members which provide a chance of meeting them, along with experts in Medicine, Parenterals and Injectables.

Parenterals and Injectables conference pledge is to provide a deep, thorough knowledge of pharmaceutical education and current novel trends in pharmaceutical sciences with the theme of “Exploring the Challenges in Parenterals and Injectables: Manufacturing and Sustainability”.

Market Analysis:
Injectables occupy a considerable prominence in world market irrespective of diminishing growth in the pharmaceutical market for 2-3 years. The advancements in technology up-gradation and investments have provided immense growth opportunities for injectables to emerge in the worlds’s pharmaceutical industry in recent years. According to RNCOS' research report, the market is anticipated to grow at a rate of approximately 4.5% during 2012-2017. The increasing need of injectables for diseases like diabetes, infectious diseases and arthritis is primarily driving the market. A lot of investment is being done in research and development of injectables in order to improve their medical outcomes.

Track 1:Novelties in Pre-filled Syringe Products:
Prefillable syringe with inbuilt inte- grated needlestick protection; which means that pharmaceutical companies buying from these syringe makers, must then secondary-package their injectable drug products, with ‘clip-on’ accessories to provide some form of needlestick protection – because this is the only way to comply with requirements for syringe-based injectable drugs to be marketed with safety- engineered sharps protection.

Track 2: Parenteral Vaccines: 
Parenteral vaccines by some route other than through the alimentary canal, such as by subcutaneous, intramuscular, intrasternal, or intravenous injection.parenteral nutrition a technique for meeting a patient's nutritional needs by means of intravenous feedings; sometimes called hyperalimentation, even though it does not provide excessive amounts of nutrients. Nutrition by intravenous feeding may be either total parenteral nutrition or only supplemental.

Track 3: Safeguard of Injectables and Leachables :
Infusions with syringe pumps,  Factors influencing the safety of device, Modification of device features for enhanced patient comfort,  Quality Concerns and Considerations Injectable Products, Analysis and safety evaluations of injectables and leachables.

Track 4: Manufacturing Considerations in Delivery Devices:
New developments in delivery devices, Improvements in micro liter dosing,  Aseptic transfer mechanisms,  Glass and plastic syringes-recent advances,  Injection site leakage-effect on drug dose etc..

Track 5: Trends and Challenges in Formulation and Development:
After oral drug administration, parenteral delivery is the second most applied route of drug administration. A steady increase in the number of parenteral drugs has led to rise in demand for various advanced drug delivery devices that ensure ease of administration as well as cost containment. 

Track 6: Pharmacology of Parenterals and Injectables:
In Parenterals Drugs are given by two general methods: enteral and parenteral administration. Enteral administration involves the esophagus, stomach, and small and large intestines (i.e., the gastrointestinal tract). Methods of administration include oral, sublingual (dissolving the drug under the tongue), and rectal. Parenteral routes, which do not involve the gastrointestinal tract, include intravenous. 

Track 7: Pharmacokinetics and Pharmacodynamics of Parenterals and Injectables:
The pharmacokinetic and pharmacodynamic effects of along-acting formulation of levonorgestrel microencapsulated in a biodegradable polymer poly(dl-lactide-co-glycolide) was tested in baboons. The polymer microspheres provided continuous release of levonorgestrel for up to 6 months following a single intramuscular injection. The treatment inhibits ovarian function for 3–6 months, depending on the dose. The duration and pattern of levonorgestrel release varies according to the quality and size of the microspheres. The microsphere delivery system offers a promising new approach to developing a long-acting injectable contraceptive based on levonorgestrel.

Track 8: Global Market Trends in Injectables and Parenterals:
Parenteral formulations are sterile liquid or solid dosages (powder) packaged in either single or multi dose containers. Intended for administration by injection or infusion, parenteral preparations provide maximum bioavailability and efficacy than the oral dosage forms. Largely, parenteral preparations are classified based on their volume into small and large volume parenteral formulations. Small volume parenteral preparations are 100 ml or less and can be prepared as single dose or multiple dose product. On the other hand, large volume parenteral (LVP) preparations are more than 100 ml solutions intended to be used as single dose intravenous infusions. Commonly used large volume parenteral formulations include intravenous infusions of amino acid, dextrose, mannitol, ringer’s injection, lactated ringer injection and sodium chloride injection. 

Track 9: Technical and Regulatory Challenges of Parenterals and Autoinjectors:
The auto-injector market is one of the fastest growing in the sector, driven by a shift towards the self-administration of widely used therapies, and a real need for market differentiation. But with market expansion has also come a bewildering range of development options, confusing for both new and established drug companies.

Track 10: Advanced Parenteral Drug Delivery System in Clinical Disease Management:
Therapeutic effect of drug depends on method by which it is delivered. Number of drug delivery system (DDS) has been developed from time immortal. One of the DDS is parenteral drug delivery system, which is firstly reported in the mid 19thcentury by Alexander wood. Since then a number of technological advances have been made in the area of parenteral drug delivery leading to the development of sophisticated systems that allow drug targeting and the sustained or controlled release of parenteral medicines. The purpose of this review is to discuss and summarize some of the interesting technologies of parenteral drug delivery system that can be helpful in the management of clinical diseases. 

Track 11: Parenteral Nutrition and Admixture:  
Parenteral nutrition (PN) is feeding a person intravenously, bypassing the usual process of eating and digestion. The person receives nutritional formulae that contain nutrients such as glucose, amino acids, lipids and added vitamins and dietary minerals. It is called total parenteral nutrition (TPN) or total nutrient admixture (TNA) when no significant nutrition is obtained by other routes. It may be called peripheral parenteral nutrition (PPN) when administered through vein access in a limb, rather than through a central vein.

Track 12: Drug Development and Designing:
Drug design, sometimes referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, drug design involves the design of small molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design frequently but not necessarily relies on computer modeling techniques. This type of modeling is often referred to as computer-aided drug design. Finally, drug design that relies on the knowledge of the three-dimensional structure of the biomolecular target is known as structure-based drug design.

Track 13: Drug Discovery:
Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology.

Track 14: Large Volume Parenteral (LVP) Solutions
Parenteral solutions are packaged as large volume parenteral (LVP) solutions and small volume parenteral (SVP) solutions. LVP solutions are typically bags or bottles containing larger volumes of intravenous solutions. Common uses of LVP solutions without additives include: 1) correction of electrolyte and fluid balance disturbances; 2) nutrition; and 3) vehicle for administering other drugs.

Track 15: Manfacturing of Parenterals
Parenteral preparations are prepared using materials and methods designed to ensure sterility and to avoid the introduction of contaminants and the growth of micro-organisms.
Methods of preparation of sterile products.
Water used in the manufacture of parenteral preparations complies with the requirements of water for injections in bulk stated in the monograph on Water for injections.
Injections: Injections are sterile solutions, emulsions or suspensions.
They are prepared by dissolving, emulsifying or suspending the active substance(s) and any added excipients in Water for injections (0169), inasuitable,sterilenon aqueous liquidor in a mixture of these vehicles. Solutions for injection, examined under suitable conditions of visibility, are clear and practically free from particles.
Emulsions for injection do not show any evidence of phase separation. Suspensions for injection may show a sediment which is readily dispersed on shaking to give a suspension which remains sufficiently stable to enable the correct dose to be withdrawn.
Infusions: Infusions are sterile, aqueous solutions or emulsions with water as the continuous phase; they are usually made isotonic with blood. They are principally intended for administration in large volume. Infusions do not contain any added antimicrobial preservative.